(-)-Epigallocatechin Gallate (EGCG) inhibits activation EGFR, HER2 and HER3 in the SW837 human colon cancer cell line. (-)-Epigallocatechin Gallate (10 μM) also inhibits cell growth, suppresses activation of EGFR, HER2, and HER3, and causes decrease in the levels of COX-2 and Bcl-xL proteins, and apoptosis after treatment for 96 h. In vivo, (-)-Epigallocatechin Gallate (5, 10, and 20 mg/kg, p.o.) inhibits the growth of orthotopic colorectal cancer cells in mice.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 20 mg/mL
Water 15 mg/mL
Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines.
De Amicis F, et al. J Cell Physiol. 2013 Oct;228(10):2054-62. PMID: 23553645.
Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling.
Jin H, et al. Onco Targets Ther. 2013;6:145-53. PMID: 23525843.
Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells.
Tsang WP, et al. J Nutr Biochem. 2010 Feb;21(2):140-6. PMID: 19269153.
|Related EGFR/HER2 Products|
ABM-3627, also known as Mutant EGFR inhibitor, is a selective and potent Mutated EGFR inhibitor.
Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation.
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.